✦ LIBER ✦

Physician Perspectives on Increasing Minorities in Cancer Clinical Trials: An Eastern Cooperative Oncology Group (ECOG) Initiative

✍ Scribed by Harlan A Pinto; Worta Mccaskill-Stevens; Pam Wolfe; Alfred C Marcus

Book ID: 117703144
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 127 KB
Volume: 10
Category: Article
ISSN: 1047-2797
DOI: 10.1016/s1047-2797(00)00191-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Utility of interphase FISH to stratify p

Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900)

✍ Gail H. Vance; Haesook Kim; Gary A. Hicks; Athena M. Cherry; Rodney Higgins; Rac 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 226 KB

We evaluated the efficacy of FISH to detect chromosome anomalies in the evaluation of young (<60 years) patients with AML. Patients were enrolled in E1900, an ECOG clinical trial for AML. The protocol was designed to collect bone marrow or blood for both cytogenetic and FISH studies at study entry (

O-086a Randomized phase II/III trial of

O-086a Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C)with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599

✍ Sandler, A.B.; Gray, R.; Brahmer, J.; Dowlati, A.; Schiller, J.H.; Perry, M.C.; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 151 KB

Post-operative radiotherapy (PORT) or ch

Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590

✍ Wakelee, Heather A.; Stephenson, Patricia; Keller, Steven M.; Wagner, Henry; Her 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 227 KB

Phase 3 randomized trial evaluating seco

Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), intergroup/clinical trials support unit study

✍ Janet R Walczak; Michael A Carducci 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 113 KB